Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Fee For Service(FFS)

Full Time Equivalent(FTE)

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Biology Research

Structural Biology

Cell Biology

Computational Biology & Molecular Modeling

Enzymology & Molecular Interactions

Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Preformulation Study

Formulation Technology Research

Preparation Quality Research

Laboratory-scale Preparation Testing

Pilot-scale Preparation Testing

GMP-based Clinical Sample Production & Packaging

Formulation Stability Study

Consistency Evaluation

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

Pharmacokinetics

In Vitro Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Chemical Drug Development
One-stop API Process R&D Department
Medicilon's CDMO Service Platform
Pharmaceutical Research CDMO Service Platform
Translational Medicine Platform
02 Innovative Drug Services
Nucleic Acid Drug R&D Platform
Non-clinical Research for Cellular Immunotherapies
mRNA Vaccine Bioanalysis Platform
PROTAC Drug Discovery Research Platform
ADC R&D Service Platform
03 Key Technical Services for Drug R&D
Green Chemistry Platform
Process Department Solid Form Screening Platform
SEND Format Conversion Platform
Flow Cytometry Technology Platform
Safety Assessment Lab of Process Chemistry
Drug Forming Research Platform
Metabolite Identification (MetID) Service Platform
Cytokine and Biomarker Detection Platform
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
IO Pharmacodynamic Model Evaluation Platform
05 Advanced Preparation R&D
Skin Topical Preparation R&D
Ophthalmic drug R&D platform
Inhalation drug R&D platform
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Downloads
Partnerships
Newsletters
U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-05-22Market Events
Meet Medicilon at SAPA-NE 25th Annual Conference

Date: Saturday, June 3rd, 2023

Location: Boston Marriott Cambridge

Learn more
2023-05-17Market Events
Stand Up for Science with Medicilon at 2023 BIO International Convention

Date: June 5-8, 2023

Location: Boston, MA

Booth: 2275-J

Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
May 25,2023
Medicilon interview with Dr. Yingfu Li - With the innovation ability in the left hand and the growth ability in the right hand, what does Hyperway Pharmaceuticals, which has only been established for 4 years, rely on it?
Shanghai Medicilon Inc. (Medicilon), as a partner of Hyperway, invited Dr. Yingfu Li, the founder of Hyperway, to reveal the secrets of Hyperway's innovation and growth.
More
Medicilon interview with Dr. Yingfu Li - With the innovation ability in the left hand and the growth ability in the right hand, what does Hyperway Pharmaceuticals, which has only been established for 4 years, rely on it?
May 12,2023
Medicilon has been listed in the "2022 China Biopharmaceutical Innovation Billboard" for two consecutive years, and won the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise"
Shanghai Medicilon Inc (Medicilon) stands out among many CROs in the country by virtue of advanced R&D technology, innovative service platform, outstanding performance and excellent market reputation, as a result, Medicilon is awarded the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise."
More
Medicilon has been listed in the "2022 China Biopharmaceutical Innovation Billboard" for two consecutive years, and won the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise"
Apr 26,2023
Medicilon's newly added facilities have obtained the GLP certification qualification of the National Medical Products Administration
On April 20, Medicilon Preclinical Research (Shanghai) LLC (MPR), has obtained the GLP (Good Laboratory Practice) certification of the National Medical Products Administration (NMPA) for the newly added facilities at Nanhui Park.
More
Medicilon's newly added facilities have obtained the GLP certification qualification of the National Medical Products Administration
Apr 10,2023
Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"
Shanghai Medicilon Inc. stood out from more than 1,500 outstanding companies and was successfully selected into the list of "2023 Shanghai Hardcore Technology Enterprises TOP 100 List". The recognition of Shanghai's hard-core technology enterprise is the official recognition of Medicilon's comprehensive R&D technology innovation, technical service platform, and drug R&D empowerment.
More
Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"
Mar 14,2023
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278). Medicilon as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and safety evaluation.
More
Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials
Mar 03,2023
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
The Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar was officially approved for sales in market. Medicilon has provided research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.
More
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
Feb 24,2023
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
CGeneTech submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the NMPA for approval. Medicilon, as a partner of CGeneTech, provided comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.
More
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
Feb 17,2023
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.
More
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Feb 03,2023
Medicilon won the "2022 Science and Technology Innovation Contribution Award" in Baoshan District, Shanghai
On January 28, 2023, the joy and excitement of the New Year still linger in the hearts. Shanghai Medicilon Inc. (Medicilon) had a good start and good news to share. Medicilon subsidiary, Medicilon (Baoshan) Inc. (Medicilon Baoshan) won the "2022 Science and Technology Innovation Contribution Award" in Baoshan District, Shanghai.
More
Medicilon won the "2022 Science and Technology Innovation Contribution Award" in Baoshan District, Shanghai
Feb 03,2023
Medicilon 19th Anniversary
Medicilon welcome the year of 2023 and also welcome the 20th year of success. 19 years of overcoming obstacles, 19 years of non-stop innovation and 19 years of R&D acceleration, Medicilon, as a professional biopharmaceutical preclinical comprehensive R&D service CRO, covers the entire process of preclinical new drug research such as drug discovery, pharmaceutical research and preclinical research, in addition of expanding the CDMO service and the global development.
More
Medicilon 19th Anniversary
Jan 06,2023
Medicilon Cell & Gene Therapy Drug R&D Service Platform
Medicilon's preclinical research services cover pharmacodynamic research, drug safety evaluation, pharmacokinetic research, bioanalysis, etc. The establishment of a complete gene therapy R&D platform can provide one-stop services for research on pharmacological efficacy, biodistribution and safety evaluation of cell and gene therapy products.
More
Medicilon Cell & Gene Therapy Drug R&D Service Platform
Jan 06,2023
2022 Memories | Medicilon Is For You
Looking back at Medicilon 2022, even the most extraordinary days never stop moving forward. Because there is always light guiding us to move forward; there is always love, shining for a long time. Thank you for the moments and memories that link us together. This accumulates as the strength to forge ahead in the New Year.
More
2022 Memories | Medicilon Is For You
Stock Code
688202

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->